



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/680,950

10/08/2003

Robert W. Langley

96-03

6033

23713 7590 02/05/2007  
GREENLEE WINNER AND SULLIVAN P C  
4875 PEARL EAST CIRCLE  
SUITE 200  
BOULDER, CO 80301

EXAMINER

DEAK, LESLIE R

ART UNIT

PAPER NUMBER

3761

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

3 MONTHS

02/05/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

**Office Action Summary**

Application No.

10/680,950

Applicant(s)

LANGLEY ET AL.

Examiner

Leslie R. Deak

Art Unit

3761

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 11 December 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-68 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-68 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 06 October 2003 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Claim Rejections - 35 USC § 112***

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 54 and 55 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

3. Claim 54 recites the limitation "the volumetric flow" in lines 3-4. Claim 55 recites the limitation "the volumetric flow" in line 3. There is insufficient antecedent basis for these limitations in the claims. Applicant fails to introduce any quantification or identification of such a "volumetric flow" in the parent claims. Accordingly, examiner is unable to determine what the recirculated component remains within 10% of. As such, examiner is unable to determine the metes and bounds of the claim. For the purposes of examination, examiner is assuming that "the volumetric flow" claimed by applicant refers to the volume of the second portion of the removed blood that is recirculating through the system, as suggested by claim 51.

### ***Claim Rejections - 35 USC § 102***

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claims 1, 2, 11, 12, 14-15, 17-22, 25-27, 40, 42-45, 47-50, 67 are rejected under 35 U.S.C. 102(b) as being anticipated by US 6,179,801 to Holmes et al.

In the specification and figures, Homes discloses the method claimed by applicant. With regard to claims 25-27, Holmes discloses a blood processing apparatus and method that comprises the steps of entering patient data into a control screen to calculate the donor's total blood volume and using the total blood volume in the determination of various parameters of the apheresis procedure (see column 56, lines 61 to column 57, line 2). Holmes specifically discloses that blood inlet pump 1030 is operated according to parameters stored in blood component separation device 6, which receives the patient parameters described above (see column 27, lines 15-25). Therefore, the removal of blood from the patient via removal pump 1030 is performed in a manner derived from the predetermined operating protocol stored in apheresis machine 6, which operates, in part, on patient blood volume data. Similarly, Homes discloses that the return rate of the blood return submode via return pump 1090 is established by blood component separation device 6 according to a predetermined protocol (see column 27, lines 15-25). As such, Holmes discloses the method claimed by applicant, meeting the limitations of the claims.

With regard to applicant's claims drawn to "systematic" variance of flow rates (eg, claims 1, 23), Holmes clearly discloses that the apheresis system 6 varies the flow rates based on a predetermined operating scheme (see column 27, lines 15-25, column 56, lines 60-67). Since the system controls such variations, Examiner considers flow rates adjusted by the apheresis system 6, including elimination of flow at the end of the

Art Unit: 3761

processing period (see column 28, lines 40-44) to correspond to applicant's "systematic" variations, since the variations are derived from the system

With regard to claims 12, 40, and 67, Holmes specifically discloses that blood is removed and returned through patient access 30 and needle 32 (see FIG 2A).

With regard to claims 42, 43, 21, and 22, Holmes discloses that the blood processing method includes a blood removal submode and a blood return submode that repeat sequentially for a predetermined amount of time (see column 28, lines 40-44).

With regard to claims 44, 45, 14, and 15, Holmes specifically discloses that the blood processing procedure may be used to separate a patient's whole blood via a centrifuge into constituent components, wherein one or more components are retained by the system (corresponding to applicant's claimed collect component) and the undesired components are returned to the patient (see column 1, lines 16-25; see also column 8, lines 20-60 for density centrifuge).

With regard to claims 47-50 and 17-20, Holmes discloses that the collected component may comprise red blood cells, white blood cells, platelets, or plasma (see column 1, lines 16-25).

With regard to claim 1, Holmes discloses that the return pump 1090 may be started and stopped according to the operating parameters of the system, thereby varying the rate of fluid return to the patient (see column 27, lines 25-35).

With regard to claim 2, Holmes discloses that the return pump 1090 is stopped after the completion of the return time (see, for example, column 28, lines 40-43). Such

Art Unit: 3761

a stoppage represents a decrease in the return flow rate, thereby meeting the limitations of the claim.

With regard to claim 11, Holmes discloses that the blood removal submode may be stopped in response to signals from the blood separation device 6, thereby halting blood removal pump 1030 (see column 27, lines 10-15). Such stopping of the blood pump is considered by the examiner to vary the rate of the removal, meeting the limitations of the claim.

***Claim Rejections - 35 USC § 103***

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. Claims 3-10, 23, 24, 28-39 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 6,179,801 to Holmes et al.

In the specification and figures, Holmes discloses the method substantially as claimed by applicant (see rejection above) with the exception of controlling the withdrawal and return rates in the specific manner claimed by applicant.

With regard to claims 3, 8, 9, and 10, Holmes specifically discloses in column 56, lines 61-67, that patient data such as patient blood volume are used to establish the operating parameters of the apheresis device 6, thereby regulating the disclosed blood processing method. In column 27, lines 15-25, Holmes teaches that the volume transfer

Art Unit: 3761

rate of blood flow is variable based on a "predetermined protocol" of the apheresis machine 6. Accordingly, this flow rate is regarded as a result-effective variable (see also at least column 28, lines 44-67 for discussion of variable flow rates). It has been held that the optimization of a result-effective variable involves only routine skill in the art. See MPEP 2144.05. In the instant case, Examiner considers the flow rates claimed by applicant (eg, increasing, decreasing, exponentially decreasing, or linearly varying) to be a result-effective variable (the adjustment of which does not patentably distinguish over the prior art of record) that may be controlled by collected and calculated patient data, thereby meeting the limitations of the claims.

With regard to claims 4-7, 30-31, and 34-39, Applicant claims to establish a return flow rate based on a specific equation. As noted above, Holmes discloses that the flow rate is recognized to be a result-effective variable. These claims establish a method for setting/optimizing various flow rates via the selection of variable/optimal parameters. Absent a disclosure that applicant's claimed equations provide a significant advantage over the prior art's calculation, Examiner considers the selection of such variable parameters to be mere optimization of a result-effective variable through routine experimentation. Holmes specifically teaches that such parameters may be selected as desired by the operator and blood handling procedure (see, generally, columns 27-28). Accordingly, as previously noted, the optimization of a variable flow rate is not considered to patentably distinguish applicant's invention from the prior art of record. See MPEP 2144.05.

With regard to claim 23, Holmes discloses that the blood removal submode may be stopped in response to signals from the blood separation device 6, thereby halting blood removal pump 1030 (see column 27, lines 10-15). Such stopping of the blood pump is considered by the examiner to vary the rate of the removal, meeting the limitations of the claims. With regard to applicant's claim limitation drawn to the ability of the method to reduce vessel infiltration, applicant discloses that such infiltration is generally a result of large pressure fluctuations while withdrawing or returning fluid to the patient's blood vessel. Holmes specifically discloses that pressure sensor 1200 senses negative and positive pressure changes in the removal tubing 22 and return tubing 26. The pressure signals are conveyed to the separation device 6, which controls the operation of removal pump 1030 and return pump 1090 (and thereby the flow rate) to maintain predetermined fluid pressures during the procedure (see column 27, lines 36-61). Holmes discloses that the pressure is controlled, which necessarily controls what applicant discloses is the cause of infiltration. It follows naturally that in controlling the pressure, the rate of infiltration is also controlled, thereby meeting the limitations of the claim.

With regard to claim 24, while increasing the removal flow rate is regarded as an optimization of a result-effective variable found in the prior art (see rejection above), Holmes specifically discloses that the blood processing method includes a blood removal submode and a blood return submode that repeat sequentially for a predetermined amount of time (see column 28, lines 40-44).



Art Unit: 3761

With regard to claims 28 and 29, as previously noted, Holmes uses the total blood volume of the patient in the determination of various parameters of the apheresis procedure (see column 56, lines 61-67). Furthermore, Holmes appears to suggest that such parameters include the withdrawal and return flow rates (see, generally, columns 27-28). Therefore, the linear correlation of the flow rate and increase of the flow rate found in the claims would be a matter of optimizing a result-effective variable found in the prior art. It has been held that the optimization of a result-effective variable involves only routine skill in the art. See MPEP 2144.05. In the instant case, Examiner considers the flow rates claimed by applicant (eg, increasing, decreasing, exponentially decreasing, or linearly varying) to be a result-effective variable (the adjustment of which does not patentably distinguish over the prior art of record) that may be controlled by collected and calculated patient data, thereby meeting the limitations of the claims.

With regard to claims 32 and 33, Applicant attempts to claim a method for determining blood volume with a formula based on patient sex, height, and weight. Holmes discloses that his procedure comprises a method for determining blood volume based on patient sex, height, and weight (see column 56, lines 48-67). Without a disclosure of how applicant's formula improves the determination of blood volume from that found in the prior art, Examiner considers the claimed formula to be merely a matter of optimizing the manner in which each procedure arrives at the patient's total blood volume. It has been held that the optimization of a result-effective variable involves only routine skill in the art. See MPEP 2144.05. In the instant case, Examiner considers

Art Unit: 3761

Applicant's selection of variable coefficients in an equation to be a matter of routine experimentation that optimizes accurate determination of patient blood volume.

8. Claims 13, 16, 41, 46, 51-68 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 6,179,801 to Holmes et al in view of US 6,730,054 to Pierce et al.

In the specification and figures, Holmes discloses the method substantially as claimed by applicant (see rejection above) with the exception of two needles to draw and return blood, an elutriation centrifugation, and a recirculation step.

With regard to claims 13 and 41, Pierce discloses a blood processing system that draws blood from a patient based on patient parameters such as patient blood volume, separates the blood into components, and returns the unused component to the patient (see column 1, lines 50-55, column 3, lines 57-63, column 12, lines 54-61). Pierce discloses that the system may comprise either a single needle blood collection system or a double needle system (see column 2, lines 65-67). Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to perform the blood processing procedure disclosed by Holmes with a two needles as disclosed by Pierce, since Pierce teaches that single and double needle processing systems are interchangeable.

With regard to claims 51 and 53, Pierce discloses a recirculation procedure that adds separated PRP to entering whole blood in order to maximize the separation of RBC and PRP to prevent contamination with RBC (see column 8, lines 54-65). As such, Pierce discloses the steps of conducting removed, anticoagulated WB through system 10, wherein the system collects RBC and PRP (see column 8, lines 29-32). The system

Art Unit: 3761

collects a portion of the PRP for further processing (corresponding to applicant's first portion), and recirculates a portion of the PRP through the system to combine with WB for increased separation efficiency (wherein the recirculated PRP corresponds to applicant's claimed second portion) (see column 8, lines 29-60). During this mode, the controller returns unused RBC and PPP (corresponding to applicant's third component) to the patient. Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to add a recirculation step as disclosed by Pierce to the blood separation and collection procedure as disclosed by Holmes, in order to provide maximal separation of RBC and PRP, as taught by Pierce.

With regard to claims 16, 46, and 56, Pierce's recirculation of PRP into the collected WB creates a secondary elutriation process that increases the separation of platelets from WB by adding extra PRP as a washing fluid to provide maximal separation of RBC and PRP. Accordingly, Pierce discloses a blood separation procedure that uses both density centrifugation and elutriation to separate the desired blood components, meeting the limitations of the claims. Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to use a washing/elutriation process as disclosed by Pierce in the blood processing procedure disclosed by Holmes, in order to increase separation efficiency, as taught by Pierce.

With regard to claim 52, Holmes discloses that the blood processing method includes a blood removal submode and a blood return submode that repeat sequentially for a predetermined amount of time (see column 28, lines 40-44).

With regard to claims 63-66, Holmes discloses that the collected component may comprise red blood cells, white blood cells, platelets, or plasma (see column 1, lines 16-25).

With regard to claims 54 and 55, Pierce is silent as to whether the system maintains steady-state flow. However, applicant merely claims “quasi” steady-state flow, which encompasses all states of flow that resemble a steady flow. Pierce discloses a blood processing system that recirculates a portion of PRP in a continuous fashion to the first stage of the processing chamber, creating a steady-state flow (column 8, lines 53-60). As such, the Pierce disclosure meets the limitations of the claims. With regard to applicant’s claim drawn to “constant within 10%,” examiner has assumed that this measurement pertains to the volume of the second portion recirculated, as set forth in parent claim 51. Pierce discloses that the entire volume of the recirculated fraction is reintroduced to the first stage of the separation vessel in a continuous fashion, meeting the limitations of the claim.

With regard to claims 57 and 58, the prior art discloses both a removed blood portion and a recirculated blood portion, each of which necessarily has a hematocrit value. This weighted average of the hematocrit values necessarily varies with the amount of blood supplied to the processing device. Pierce does not provide any limitation to the amount of fluid supplied to the recirculation loop, but does disclose that the amount is sufficient to establish desired conditions in the blood separation system. Therefore, Pierce suggests that the amount of recirculated portion may be selected to maximize a desired result—efficient separation of RBC and PRP. It has been held that

the optimization of a result-effective variable involves only routine skill in the art. See MPEP 2144.05. In the instant case, the portion of the recirculated flow is selected to provide the result of maximum separation of RBC and PRP.

With regard to claims 59-62 and 68, as noted above, each portion of blood necessarily has a hematocrit value, and the draw and return cycles each have a rate (see rejections above). Applicant uses an equation to set the duration of each cycle. Both Holmes and Pierce teach that the method comprises draw and return cycles. Broadly defined, a cycle comprises an interval of time (see Merriam-Webster's Collegiate Dictionary, 10<sup>th</sup> Ed., 2001). All the values used in the determination of  $F_{c\max}$  in the claimed equation are demonstrated by the prior art to be variable. It has been held that the optimization of a result-effective variable involves only routine skill in the art. See MPEP 2144.05. In the instant case, the duration of the draw and return cycles are varied in order to provide a sufficient amount of time to provide blood to the separation system and to return components to the donor, respectively. (see Pierce, column 7, lines 45-50). Accordingly, Examiner considers the selection of such variable parameters to be mere optimization of a result-effective variable through routine experimentation.

### ***Response to Amendment/Arguments***

9. Applicant's amendment filed 11 December 2006 has been entered and fully considered. Applicant's amendments to claims 54 and 55 have rendered moot the 25

USC 112 rejection presented in the nonfinal Office Action. However, applicant's amendment creates a new grounds for rejection, presented above.

10. Applicant's arguments filed 11 December have been fully considered but they are not persuasive.

11. Applicant argues that the Holmes specification fails to disclose the step of using the patient's total blood volume to alter the rate of withdrawal and return of blood to and from the patient as recited in claim 27, instead, relying on pressure measurements to control the operation of the withdrawal and return rates.

Examiner notes that the claims recite the use of patient total blood volume to *control* blood flow rates, not *alter* them as argued by applicant. Applicant specifically argues that the pressure transducers disclosed by Holmes operate the blood inlet 1030 and return 1090 pumps during operation. However, applicant does not *claim* the step of using total blood volume to alter blood flow rates during operation. Applicant merely claims that the total blood volume is used to set a removal and return flow rate, which may occur at the beginning of the procedure, without intraprocedure adjustments.

Holmes specifically discloses that the patient's total blood volume 4 may be utilized in the determination of various parameters associated with the apheresis procedure (see column 56, lines 65-67). One parameter of an apheresis procedure is the rate of withdrawal and return of blood to the patient. As such, the total blood volume of the patient may be used to control the rate of withdrawal and return, meeting the limitations of the claims.

12. Applicant's further argues that Holmes does not disclose systematic variation of flow rates during the claimed method. Specifically, applicant argues that the definition of "systematic" variations as provided by the specification refers to variations that are substantially linear, exponential, logarithmic, or quadratic. As pointed out by applicant, Holmes does not disclose linear, exponential, logarithmic, or quadratic variations in flow rates. However, applicant's definition of "systematically varying" on page 19 of the specification does not limit variations to the four types listed above. The specification defines "systematically varying" as a process whereby a parameter is manipulated in a controlled manner. The specification specifically points out that the variations *may be* substantially linear, exponential, logarithmic, or quadratic, but does not limit the variations to those four types. As such, Holmes discloses systematic, or controlled variations as defined by applicant, meeting the limitations of the claims.

13. Applicant argues that Holmes does not disclose or suggest that blood flow rate is not a result-effective variable, the optimization of which is an obvious variation on the prior art. Applicant specifically argues that Holmes does not disclose using total blood volume of the donor to adjust removal or return rate of blood. However, applicant does not specifically claim that variations in blood rate are controlled by total blood volume of the patient. Applicant claims that the total blood volume is used to derive blood removal and return flow rate in claims 25-27. Such derivation may occur at any time during the procedure, such as the beginning of the procedure at which time the apheresis parameters are set, as suggested by Holmes in column 56, lines 61-67. Applicant does *not* specifically claim that total blood volume of the patient is used to make adjustments

Art Unit: 3761

or variations to the flow rate during the procedure—only that such rates are systematically varied, or varied in a controlled fashion, during the procedure. Applicant does not recite that the variations are made based on total blood volume. Since Holmes discloses that the blood flow rates may be varied in a controlled fashion from measured parameters, the Holmes disclosure suggests that variation of the flow rates is a result-effective variable, optimization of which is a matter of routine skill in the art.

14. Applicant further argues that Pierce fails to disclose that the recirculating component remains within 10% of volumetric flow. However, applicant fails to define volumetric flow as set forth in the rejection above. Pierce discloses that the entire volume of the collected and recirculated fraction is recirculated into the separation vessel. The entire volume is the complete volume, which is within 10% of the original volume of collected component, meeting the limitations of the claims.

15. With regard to claims 57-58, applicant argues that there is no suggestion in the prior art that varying the hematocrit value of the blood components to control the efficacy of a blood separation system is the obvious optimization of a result-effective variable. However, applicant does not claim the use of hematocrit values to control the efficacy of the separation system. Applicant merely claims that the separated portions comprise certain hematocrit values. Pierce specifically discloses that the volume of the portions are selected to maximize the RBC and PRP separation. As such, the volume of the portions selected by Pierce may comprise the hematocrit values claimed by applicant, meeting the limitations of the claims.



Art Unit: 3761

16. With regard to claims 59-62 and 68, applicant argues that the variation of the duration of the draw and return cycles is not the obvious optimization of a result-effective variable.

However, claim 51 sets forth that the volume of collected component,  $F_{cmax}$ , is selected to prevent contamination between the collected component and RBCs. Pierce discloses that the amount of collected component is selected to maximize the efficiency of separation, resulting in little contamination of PRP (the collect component) with RBCs. Collection efficiency depends on several variables, including blood flow rate, hematocrit, and cycle time (see Pierce, equations 6, 7, and 19). As such, varying parameters of the blood collection and separation procedure in order to optimize efficiency of the collection procedure is an obvious manipulation of the result effective variables (flow rate, hematocrit values, and cycle time) in order to optimize the efficiency of the blood collection and separation procedure disclosed in the prior art.

17. Accordingly, the pending claims remain rejected over the prior art of record.

### ***Conclusion***

18. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the

Art Unit: 3761


shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leslie R. Deak whose telephone number is 571-272-4943. The examiner can normally be reached on M-F 7:30-5:00, every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tanya Zalukaeva can be reached on 571-272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

TATYANA ZALUKAEVA  
SUPERVISORY PRIMARY EXAMINER



Leslie R. Deak  
Patent Examiner  
Art Unit 3761  
23 January 2007